Evidence map›Paper›PMID 30407715›Full record

ArticleCancer science2019

MORC2 promotes development of an aggressive colorectal cancer phenotype through inhibition of NDRG1.

Jiao Liu, Yangguang Shao, Yuxin He, Ke Ning, Xi Cui, Furong Liu, Zhenning Wang, Feng Li

Open access · goldAbstract read
In one paragraph

Article in Cancer science, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 47 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Oncology research · 2025
    Article
  5. Review
  6. Emerging roles of the chromatin remodeler MORC2 in cancer metabolism.Medical oncology (Northwood, London, England) · 2024
    Review
  7. Article
  8. Article
  9. Article
  10. The Role of theAnimals : an open access journal from MDPI · 2024
    Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. The Roles of Zinc Finger Proteins in Colorectal Cancer.International journal of molecular sciences · 2023
    Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Jiao LiuDepartment of Cell Biology, Key Laboratory of Cell Biology, National Health Commission of the PRC, and Key Laboratory of Medical Cell Biology, Ministry of Education of the PRC, China Medical University, Shenyang, China.
Yangguang ShaoDepartment of Cell Biology, Key Laboratory of Cell Biology, National Health Commission of the PRC, and Key Laboratory of Medical Cell Biology, Ministry of Education of the PRC, China Medical University, Shenyang, China.
Yuxin HeDepartment of Cell Biology, Key Laboratory of Cell Biology, National Health Commission of the PRC, and Key Laboratory of Medical Cell Biology, Ministry of Education of the PRC, China Medical University, Shenyang, China.
Ke NingDepartment of Cell Biology, Key Laboratory of Cell Biology, National Health Commission of the PRC, and Key Laboratory of Medical Cell Biology, Ministry of Education of the PRC, China Medical University, Shenyang, China.
Xi CuiDepartment of Cell Biology, Key Laboratory of Cell Biology, National Health Commission of the PRC, and Key Laboratory of Medical Cell Biology, Ministry of Education of the PRC, China Medical University, Shenyang, China.
Furong LiuDepartment of Cell Biology, Key Laboratory of Cell Biology, National Health Commission of the PRC, and Key Laboratory of Medical Cell Biology, Ministry of Education of the PRC, China Medical University, Shenyang, China.
Zhenning WangDepartment of Surgical Oncology and General Surgery, First Hospital of China Medical University, Shenyang, China.ORCID http://orcid.org/0000-0003-0557-3097
Feng LiDepartment of Cell Biology, Key Laboratory of Cell Biology, National Health Commission of the PRC, and Key Laboratory of Medical Cell Biology, Ministry of Education of the PRC, China Medical University, Shenyang, China.ORCID http://orcid.org/0000-0001-5868-7456
National Health and Family Planning Commission · CNFirst Hospital of China Medical University · CN

Funding

National Natural Science Foundation of China 31271389National Natural Science Foundation of China 31571457National Natural Science Foundation of China 31771553Scientific and Technological Research Project of Liaoning Provincial Education Department LK201630
6 · The paper itself

Abstract

MORC2 (microrchidia family CW-type zinc finger 2) is a newly identified chromatin remodeling protein that functions in diverse biological processes including gene transcription. NDRG1 is a metastasis suppressor and a prognostic biomarker for colorectal cancer (CRC). However, the relationship between MORC2 and NDRG1 transcriptional regulation and the roles of MORC2 in CRC remain elusive. Here, we showed that MORC2 downregulated NDRG1 mRNA, protein levels, and promoter activity in CRC cells. We also found that MORC2 bound to the -446 to -213 bp region of the NDRG1 promoter. Mechanistically, histone deacetylase sirtuin 1 (SIRT1) was involved in NDRG1 transcriptional regulation. MORC2 was able to interact with SIRT1 and inhibit NDRG1 promoter activity cumulatively with SIRT1. MORC2 overexpression led to a decrease of H3Ac and H4Ac of the NDRG1 promoter. Importantly, we showed that NDRG1 was essential in MORC2-mediated promotion of CRC cell migration and invasion in vitro, as well as lung metastasis of CRC cells in vivo. Moreover, MORC2 expression correlated negatively with NDRG1 expression in CRC patients. High expression of MORC2 was significantly associated with lymph node metastasis (P = 0.019) and poor pTNM stage (P = 0.02) and the expression of MORC2 correlated with poor prognosis in colon cancer patients. Our findings thus contribute to the knowledge of the regulatory mechanism of MORC2 in downregulating NDRG1, and suggest MORC2 as a potential therapeutic target for CRC.

Indexed as

Gene Expression ProfilingGene Expression Regulation, NeoplasticAgedAnimalsCell Cycle ProteinsCell Line, TumorColorectal NeoplasmsFemaleHEK293 CellsHT29 CellsHumansIntracellular Signaling Peptides and ProteinsLymphatic MetastasisMaleMice, Inbred BALB CMice, NudeCell Cycle ProteinsIntracellular Signaling Peptides and ProteinsMORC2 protein, humanN-myc Downstream-Regulated Gene 1 ProteinTranscription Factorscolorectal cancerMORC2NDRG1SIRT1transcriptional regulation

Identifiers

PMID30407715
PMCPMC6317918
OpenAlexW2900376330

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.